ArticleBMC infectious diseases2025
Evaluating the impact of trade-offs in diagnostic test accuracy, time-to-isolation, and accessibility on outbreak response for the Ebola virus: a mathematical modeling study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- When detecting Ebola is not enough: closing the response interval in DRC.Nature medicine · 2026Article
- Decentralizing testing capacity of mpox in Africa: a narrative review.The Lancet regional health. Africa · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEbolavirus and related filoviruses are feared pathogens due to high mortality rates, and cases are confirmed using reverse transcription-polymerase chain reaction (RT-PCR) testing. Compared to rapid diagnostic testing (RDT), RT-PCR has higher accuracy but longer turnaround time and lower testing rate. RDTs' accuracy for Ebola does not meet the World Health Organization's (WHO) target product profile (TPP). This TPP, however, excludes trade-offs between accuracy, time-to-isolation (the time from getting tested to getting hospitalized and isolated), and accessibility. This research aims to guide diagnostic test development and use by identifying trade-offs in accuracy, time-to-isolation, and accessibility that enable impactful outbreak response.
methodsA mathematical compartmental model was calibrated to the 2014-2016 Sierra Leone EBOV epidemic, including test accuracy, accessibility, and time-to-isolation parameters. These parameters were varied to evaluate their impact on total epidemic size in different in isolation and in combination.
resultsReductions in EBOV test sensitivity or specificity alone will increase the expected number of cases from 11.7 to 223%, while any decrease in time-to-isolation alone (due to a more rapid test result) or increase in testing rate alone would decrease the expected number of cases by 47.7-87.7%. When combining the three factors together, the benefits associated with an RDT would outweigh the harms, with a combined net reduction of mean cases between 71.6 and 92.3%.
conclusionsWhen coupled with a more rapid turnaround time and increase in test access, the use of a lower performance test can result in significantly reduced epidemic size compared to relying on PCR alone in an EBOV outbreak in a resource-limited setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.